TOP TEN perturbations for 39734_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39734_at
Selected probe(set): 202542_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39734_at (202542_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
endometriosis study 6 (moderate/severe endo.; pro. MCP) / endometriosis study 6 (moderate/severe endo.; mid-se MCP)
Relative Expression (log2-ratio):-2.308857Number of Samples:17 / 19
| Experimental | endometriosis study 6 (moderate/severe endo.; pro. MCP) |
| Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | endometriosis study 6 (moderate/severe endo.; mid-se MCP) |
| Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual phase cycle (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
endometriosis study 6 (minimal/mild endo.; mid-se MCP) / normal endometrium tissue (mid-se MCP)
Relative Expression (log2-ratio):-2.1031914Number of Samples:9 / 8
| Experimental | endometriosis study 6 (minimal/mild endo.; mid-se MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (mid-se MCP) |
| Normal endometrial tissue samples from women collected in the mid-secretory menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-2.0971117Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):-2.0845528Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 12d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):-2.0719242Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 15d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
FoxO3 H212R overexpr. study 1 / FoxO3 overexpr. study 1
Relative Expression (log2-ratio):-2.0101032Number of Samples:3 / 3
| Experimental | FoxO3 H212R overexpr. study 1 |
| Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- | |
| Control | FoxO3 overexpr. study 1 |
| Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- |
medulloblastoma study 2 / non-tumor brain tissue
Relative Expression (log2-ratio):2.0057182Number of Samples:4 / 9
| Experimental | medulloblastoma study 2 |
| Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma. | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
ovulation study 2 / proliferative phase endometrium tissue
Relative Expression (log2-ratio):1.9782019Number of Samples:8 / 4
| Experimental | ovulation study 2 |
| Mid secretory phase (MSE) endometrium tissue. | |
| Control | proliferative phase endometrium tissue |
| Proliferative phase (PE) endometrium tissue. |
tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):1.8974056Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):1.8353729Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |